| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/02/2023 | 6.21% | Citigroup | $90 → $94 | Maintains | Neutral |
| 08/09/2023 | 28.81% | Barrington Research | $111 → $114 | Maintains | Outperform |
| 05/12/2023 | 25.42% | Barrington Research | $103 → $111 | Maintains | Outperform |
| 05/12/2023 | 8.47% | Morgan Stanley | $88 → $96 | Maintains | Equal-Weight |
| 05/12/2023 | 29.94% | JMP Securities | $105 → $115 | Maintains | Market Outperform |
| 02/08/2023 | -0.57% | Morgan Stanley | $84 → $88 | Maintains | Equal-Weight |
| 02/08/2023 | 7.34% | Citigroup | $92 → $95 | Maintains | Neutral |
| 02/08/2023 | 16.38% | Barrington Research | $94 → $103 | Maintains | Outperform |
| 02/08/2023 | 29.94% | Mizuho | $110 → $115 | Maintains | Buy |
| 01/24/2023 | 24.29% | Mizuho | $100 → $110 | Maintains | Buy |
| 01/06/2023 | -5.09% | Morgan Stanley | $90 → $84 | Maintains | Equal-Weight |
| 12/12/2022 | 3.95% | Citigroup | $88 → $92 | Maintains | Neutral |
| 11/08/2022 | 6.21% | Barrington Research | $88 → $94 | Maintains | Outperform |
| 11/08/2022 | 1.69% | Morgan Stanley | $85 → $90 | Maintains | Equal-Weight |
| 11/08/2022 | 12.99% | Mizuho | $90 → $100 | Maintains | Buy |
| 11/08/2022 | 18.64% | JMP Securities | $90 → $105 | Maintains | Market Outperform |
| 11/08/2022 | 12.99% | Raymond James | $88 → $100 | Maintains | Outperform |
| 11/08/2022 | -0.57% | Citigroup | $80 → $88 | Maintains | Neutral |
| 10/13/2022 | 1.69% | Mizuho | → $90 | Initiates Coverage On | → Buy |
| 10/11/2022 | -3.96% | Morgan Stanley | $74 → $85 | Maintains | Equal-Weight |
| 08/11/2022 | 1.69% | JMP Securities | $80 → $90 | Maintains | Market Outperform |
| 08/11/2022 | -16.39% | Morgan Stanley | $70 → $74 | Maintains | Equal-Weight |
| 08/11/2022 | -0.57% | Barrington Research | $77 → $88 | Maintains | Outperform |
| 08/11/2022 | -0.57% | Raymond James | $76 → $88 | Maintains | Outperform |
| 07/01/2022 | -20.91% | Morgan Stanley | $60 → $70 | Maintains | Equal-Weight |
| 07/01/2022 | -14.13% | Raymond James | $63 → $76 | Maintains | Outperform |
| 05/11/2022 | -32.21% | Morgan Stanley | $64 → $60 | Maintains | Equal-Weight |
| 05/11/2022 | -28.82% | Raymond James | $66 → $63 | Maintains | Outperform |
| 02/09/2022 | -25.43% | Raymond James | $70 → $66 | Maintains | Outperform |
| 01/27/2022 | — | Needham | Downgrades | Buy → Hold | |
| 01/07/2022 | -32.21% | Morgan Stanley | $68 → $60 | Maintains | Equal-Weight |
| 12/15/2021 | — | Citigroup | Downgrades | Buy → Neutral | |
| 11/10/2021 | -9.61% | JMP Securities | $90 → $80 | Maintains | Market Outperform |
| 11/10/2021 | -20.91% | Raymond James | $75 → $70 | Maintains | Outperform |
| 06/17/2021 | -15.26% | Citigroup | → $75 | Initiates Coverage On | → Buy |
| 05/14/2021 | — | CJS Securities | Upgrades | Market Perform → Outperform | |
| 05/14/2021 | 1.69% | JMP Securities | $110 → $90 | Maintains | Market Outperform |
| 05/14/2021 | -3.96% | Jefferies | $105 → $85 | Maintains | Buy |
| 05/14/2021 | -15.26% | Morgan Stanley | $83 → $75 | Maintains | Equal-Weight |
| 04/20/2021 | -6.22% | Morgan Stanley | $147 → $83 | Downgrades | Overweight → Equal-Weight |
| 04/20/2021 | 22.03% | Needham | $158 → $108 | Maintains | Buy |
| 04/20/2021 | 2.82% | Barrington Research | $140 → $91 | Maintains | Outperform |
| 04/19/2021 | 22.03% | Needham | $158 → $108 | Maintains | Buy |
| 02/12/2021 | 75.13% | Raymond James | $145 → $155 | Maintains | Outperform |
| 02/03/2021 | 58.18% | Barrington Research | → $140 | Upgrades | Market Perform → Outperform |
| 02/03/2021 | 66.09% | Morgan Stanley | $139 → $147 | Maintains | Overweight |
| 02/03/2021 | 63.83% | Raymond James | $135 → $145 | Maintains | Outperform |
| 01/21/2021 | — | Barrington Research | Downgrades | Outperform → Market Perform | |
| 01/20/2021 | 60.44% | Needham | $122 → $142 | Maintains | Buy |
| 01/07/2021 | 52.53% | Raymond James | $130 → $135 | Maintains | Outperform |
| 12/15/2020 | 57.05% | Morgan Stanley | $110 → $139 | Maintains | Overweight |
| 11/05/2020 | — | Barrington Research | Upgrades | Market Perform → Outperform | |
| 11/02/2020 | 46.88% | Raymond James | $100 → $130 | Maintains | Outperform |
| 09/08/2020 | 12.99% | Raymond James | $93 → $100 | Maintains | Outperform |
| 08/05/2020 | 5.08% | Raymond James | $113 → $93 | Maintains | Outperform |
| 07/08/2020 | 24.29% | Morgan Stanley | $138 → $110 | Maintains | Overweight |
| 07/01/2020 | 27.68% | Raymond James | $125 → $113 | Maintains | Outperform |
| 05/06/2020 | 41.23% | Raymond James | $130 → $125 | Maintains | Outperform |
| 05/05/2020 | 49.14% | Needham | $142 → $132 | Maintains | Buy |
| 04/07/2020 | 46.88% | Raymond James | $150 → $130 | Maintains | Outperform |
| 03/27/2020 | 55.92% | Morgan Stanley | $148 → $138 | Maintains | Overweight |
| 02/05/2020 | 69.48% | Raymond James | $145 → $150 | Maintains | Outperform |
| 01/23/2020 | 63.83% | Raymond James | $150 → $145 | Maintains | Outperform |
| 01/10/2020 | 55.92% | Needham | → $138 | Initiates Coverage On | → Buy |
| 08/07/2019 | 67.22% | Morgan Stanley | $128 → $148 | Maintains | Overweight |
| 08/07/2019 | 69.48% | Raymond James | $110 → $150 | Maintains | Outperform |
| 05/14/2019 | 24.29% | Raymond James | → $110 | Upgrades | Market Perform → Outperform |
What is the target price for Haemonetics (HAE)?
The latest price target for Haemonetics (NYSE: HAE) was reported by Citigroup on October 2, 2023. The analyst firm set a price target for $94.00 expecting HAE to rise to within 12 months (a possible 6.21% upside). 20 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Haemonetics (HAE)?
The latest analyst rating for Haemonetics (NYSE: HAE) was provided by Citigroup, and Haemonetics maintained their neutral rating.
When is the next analyst rating going to be posted or updated for Haemonetics (HAE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Haemonetics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Haemonetics was filed on October 2, 2023 so you should expect the next rating to be made available sometime around October 2, 2024.
Is the Analyst Rating Haemonetics (HAE) correct?
While ratings are subjective and will change, the latest Haemonetics (HAE) rating was a maintained with a price target of $90.00 to $94.00. The current price Haemonetics (HAE) is trading at is $88.51, which is out of the analyst's predicted range.